BACKGROUND The hepatosplenic schistosomiasis(HSS)with portal hypertension can cause vascular complications such as hepatopulmonary syndrome(HPS).HPS increases the risk of mortality in patients with cirrhosis;however,t...
Portal hypertension caused by non-cirrhotic(and non neoplastic)splanchnic vein thrombosis(NC-SVT)is responsible for 5–10%of portal hypertension cases in the western world(1).Chronic myeloproliferative neoplasms(MPN)o...
Hepatocellular carcinoma(HCC)is the sixtieth most prevalent cancer and the third cause of cancer-related mortality worldwide(1).HCC occurs in the context of liver disease,with around 85%of liver cancers developing in ...
Non-cirrhotic non-malignant portal vein thrombosis(NCPVT)is an uncommon condition characterised by thrombosis of the portal vein,with or without extension into other mesenteric veins,in the absence of cirrhosis or int...
the National Natural Science Foundation of China(82173353);Top talent scientific research project of“six one projects”(LGY2018028).
Background:About 10%-20%of all individuals who develop hepatocellular carcinoma(HCC)do not have cirrhosis.Comparisons are rarely reported regarding the effectiveness of radiofrequency ablation(RFA)and liver resection(...
Cirrhosis is an emerging major cause of the development of hepatocellular carcinoma(HCC),but in non-alcoholic fatty liver disease(NAFLD),up to 50%of patients with HCC had no clinical or histological evidence of cirrho...
Non-cirrhotic portal hypertension(NCPH)forms an important subset of portal hypertension in children.Variceal bleed and splenomegaly are their predominant presentation.Laboratory features show cytopenias(hypersplenism)...
Hepatitis C virus genotype 4(HCV-GT4)is a risk factor for cirrhosis,hepatocellular carcinoma and liver failure.A combination of three new direct-acting antivirals ombitasvir,paritaprevir,and ritonavir has been recomme...
Primary liver cancers carry significant morbidity and mortality.Hepatocellular carcinoma(HCC)develops within the hepatic parenchyma and is the most common malignancy originating from the liver.Although 80%of HCCs deve...
Austrian Science Fund FWF,No.J4396;Wellcome Trust PhD Fellowship for Clinicians,No.UNS59491.
The obesity pandemic has led to a significant increase in patients with metabolic dysfunction-associated fatty liver disease(MAFLD).While dyslipidemia,type 2 diabetes mellitus and cardiovascular diseases guide treatme...